#United States #Traws Pharma #Dover, Delaware #Expert Systems Inc. #Ratutrelvir

Expert Systems Inc. Supports Traws Pharma's Phase 2 Studies

DOVER, Del., Oct. 22, 2025 — In a significant move for the fight against COVID-19, Expert Systems Inc., a prominent life sciences accelerator, has announced ongoing support for Traws Pharma (NASDAQ: TRAW) as the latter embarks on Phase 2 clinical trials for Ratutrelvir (TRX01), a promising oral antiviral treatment for newly diagnosed COVID-19 patients.

Overview of Ratutrelvir

Ratutrelvir is a next-generation antiviral designed as a ritonavir-free option, addressing major challenges faced by COVID patients. Traditional antiviral treatments often require ritonavir, which can lead to harmful drug interactions that exclude roughly 20% of COVID patients who might benefit from protease inhibitors. In contrast, Ratutrelvir’s formulation allows for effective treatment without these complications, making it an essential development in the ongoing management of COVID-19.

The drug exhibited broad-spectrum in vitro activity against various SARS-CoV-2 strains, showcasing exceptional potency profiles. Expert Systems utilized cutting-edge predictive pharmacology and AI-driven molecular modeling to optimize Ratutrelvir's pharmacokinetics, safety, and effectiveness—ensuring that it can be administered across a wide range of therapeutic and preventive scenarios.

Clinical Trial Design

The Phase 2 program, authorized in the third quarter of 2025 following successful Phase 1 studies, consists of two main trials:
1. A non-inferiority trial that compares Ratutrelvir with the well-established antiviral PAXLOVID® in newly diagnosed patients.
2. A single-arm trial focusing on populations ineligible for PAXLOVID®, targeting a crucial demographic that is at a heightened risk of experiencing severe COVID-19 outcomes.

Dr. Tudor Oprea, CEO of Expert Systems Inc., emphasized the importance of this research. He stated, "COVID-19 continues to present significant public health challenges, especially to older and immunocompromised individuals who often lack access to the current standard-of-care options. By leveraging our advanced AI and machine learning capabilities, we have optimized a differentiated antiviral that stands out in the evolving landscape of COVID-19 treatments."

Results of Previous Trials

The Phase 1 multiple ascending dose studies highlighted Ratutrelvir's promising profile, with a daily oral dosage of 600 mg maintaining plasma concentrations approximately 13 times higher than the effective concentration (EC50) for the full 10-day treatment duration. Furthermore, the trough levels remained above the EC90 threshold, which is crucial for mitigating the risk of viral rebound after treatment cessation. Expert Systems' predictive modeling indicates even higher drug concentrations in lung tissue compared to plasma, enhancing antiviral exposure directly at the infection site, where it is most needed.

Expert Systems' Role

As the studies progress, Expert Systems will provide crucial strategic, scientific, and technological support to ensure that Ratutrelvir achieves its clinical objectives. This collaboration underscores Expert Systems’ expertise in applying computational design and predictive pharmacology to minimize risks associated with drug development and to accelerate the translation of promising therapeutics into clinical practice.

About Expert Systems Inc.

Established as a leader in advancing precision therapeutics through innovative AI and machine learning, Expert Systems Inc. integrates various core competencies in rational drug design, translational modeling, and regulatory strategy. The company has a robust history of assisting over 30 R&D initiatives funded by investors in North America, Europe, and Australia. By effectively reducing timelines from conceptualization to clinical trials, Expert Systems transforms pioneering science into ready-to-invest clinical applications.

In conclusion, as Traws Pharma moves forward with its Ratutrelvir trials, the partnership with Expert Systems exemplifies a concerted effort to combat COVID-19 with next-generation antiviral solutions that promise improved patient outcomes and access to effective treatments.